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Abstract
Iron deficiency anaemia as the most common nutrition disorder has only marginal reduc-
tion globally during recent decades, with the highest burden in pregnant women and 
young children. Insufficient iron storage and/or excessive loss of iron are common causes 
of iron deficiency anaemia. Therefore, understanding the complexity of the regulatory 
network required to maintain iron homeostasis and identifying the functional variants 
associated with iron metabolism should be fundamental and crucial to control and treat 
the iron deficiency anaemia. Sensitive and inexpensive measures to distinguish iron 
deficiency anaemia from the other kinds of anaemia should be developed for precise 
treatment. Original disease treatments combined with oral or intravenous iron therapy 
are key approaches in clinical practices. The integrated, multifactorial and multi‐sectoral 
approach with food‐based strategy and iron supplementation as the leading public health 
inventions is required to achieve iron deficiency anaemia control target. This chapter will 
focus on the advanced knowledge associated with iron metabolism, disease burden and 
health consequences of iron deficiency anaemia in different life course, newly parameters 
development in the diagnosis of iron deficiency anaemia, therapy choice in clinical prac-
tice and public health strategies to reduce iron deficiencies in high‐burden areas.
Keywords: iron deficiency, iron deficiency anaemia, iron metabolism, hepcidin, iron 
supplementation, food fortification, ferritin, transferrin saturation
1. Introduction
As the most common nutrition disorder in both the developed and developing world, affect-
ing more than two billion people, iron deficiency anaemia is recognized not only a clinical 
condition but also a serious public health issue, with pregnancy women and pre‐school‐age 
children at the highest risk [1–5]. The annual economic loss because of iron deficiency anaemia 
© 2018 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
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in 10 developing countries was estimated about 4% of gross domestic product [2]. Despite 
considerable economic and scientific advancement during recent decades, there has been only 
marginal reduction in the global prevalence of anaemia with more than 50% of cases caused 
by iron deficiency [2, 4].
This chapter will summarize the advanced knowledge associated with iron metabolism, 
health burden, newly parameters development in the diagnosis of iron deficiency anaemia, 
therapy choice and public health strategies to reduce iron deficiencies in high burden areas.
2. Iron metabolism and hepcidin, potential regulators associated with 
iron metabolism
2.1. Iron metabolism pathway
The absorption of dietary iron is a variable and dynamic process, depending on the two primary 
forms of haem and non‐haem iron. Haem is a component of haemoglobin and myoglobin 
and haem iron is complexed as ferrous iron (Fe2+) in the haem form, which is present in ani-
mal tissues such as meat, poultry, fish and shellfish [6]. Most of non‐haem iron (Fe3+ or ferric 
iron) is provided by the vegetarian diet (black tea, cacao, cereals, dried fruit etc.). Although 
haem iron could represent ∼40% of animal tissue iron and be better absorbed, it only accounts 
for less than 15% of total iron intake [7, 8]. In spite of the low absorption rate, the majority 
of the dietary iron is obtained from non‐haem iron. Studies have confirmed that animal tis-
sues (meat, poultry and fish) and vitamin C and organic acids could enhance iron absorption, 
while high intake of phytates, tannins, calcium and zinc may tend to inhibit the absorption of 
iron [9, 10].
It is currently well known that most of dietary iron is absorbed by enterocytes of the duo-
denal lining. The first step to absorb iron is that the insoluble ferric iron (Fe3+) has to be con-
verted into the ferrous form (Fe2+) by a brush border ferric reductase (duodenal cytochrome B, 
DCYTB) in the duodenum and upper jejunum. The ferrous iron is then transferred across the 
enterocyte membrane into the cell by divalent metal transporter 1 (DMT1). Afterwards, the 
iron is stored in these intestinal lining cells as ferritin which is accomplished by Fe3+ binding 
to apoferritin, or could be released into the body via the only known iron exporter ferroportin. 
Cooperated with either of the ferroxidases hephaestin (enterocytes) or ceruloplasmin (other 
cell types) that facilitate iron extraction from the ferroportin channel, ferroportin at the baso-
lateral membrane transports Fe2+ that is subsequently loaded onto plasma transferrin (Tf) [11].
In blood, plasma iron‐loaded transferrin (Tf‐Fe2+) transports iron to all cells in a transferrin 
receptor‐mediated endocytotic process [6]. Iron‐loaded Tf binds to transferrin receptor 1 (TfR1), 
and their complex internalizes and enters into cells, wherein iron releases by pH‐dependent 
mechanism. As it provides most of the iron required for various functions of an organism, 
plasma transferrin plays a crucial role in iron metabolism. TfR1 is highly expressed on haemo-
globin‐synthesizing erythroblasts. Most of plasma iron is used by bone marrow to synthesize 
haemoglobin in red blood precursors. Several other cell types, such as enterocytes, hepato-
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cytes and reticuloendothelial macrophages, are considered to be major iron storage sites. Iron 
release from or store in enterocytes, hepatocytes and macrophages depends on plasma iron 
levels, to meet the physiological demand. In a review published in Cell, Hentze et al. carefully 
discussed these mechanisms and summarized them in a single figure (Figure 1) [11].
2.2. Hepcidin and potential regulators associated with iron metabolism
In the human body, the iron homeostasis is tightly regulated to avoid both deficiency and 
excess. Hepcidin is a core regulator of the entry of iron into the circulation, which is a peptide 
hormone synthesized mainly in the liver, which was discovered in 2000. Previous studies have 
confirmed that hepcidin is not liver specific but also expressed in other tissues, such as the 
kidney, heart and lungs [12]. Hepcidin is first synthetized as an 84‐amino acid (aa) prepropep-
tide, and then further processed into 60–64‐aa prohepcidin. Finally, mature and biologically 
active 25‐aa hepcidin is produced by truncating the proregion from prohormon convertase 
furin [13]. When the hepcidin level is abnormally high, serum iron falls due to iron trapping 
in macrophages and liver cells, and decreased gut iron absorption by reducing iron transport 
across the gut mucosa (enterocytes). In the instances, it is clear that anaemia will develop due 
Figure 1. Mechanism of systemic iron metabolism. Derived from: Hentze et al. [11].
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to lack of inadequate amount of serum iron being available for developing red cells. In the 
state in which the hepcidin level is abnormally low, on the contrary, iron overload occurs due 
to increased iron efflux from storage and gut iron absorption. Tandara et al. have discussed 
the mechanisms of hepcidin regulating iron homeostasis and summarized them in a single 
figure (Figure 2) [14].
So far, at least four major separate pathways in hepcidin regulation have been confirmed, 
such as regulation by iron status; dietary iron and iron stores; regulation by inflammation; 
regulation by hypoxia/anaemia and regulation by erythroid factors [15, 16]. These different 
regulatory inputs are integrated transcriptionally.
At the molecular level, it is not still completely clear that iron stores regulate hepcidin syn-
thesis, but haemojuvelin (HJV), haemochromatosis protein (HFE) and transferrin receptor 2 
(TfR2) have been proven to be upstream regulators of hepcidin. HFE acts as a bimodal switch 
between two sensors of the concentration of Tf‐Fe2+, TfR1 and TfR2, on the plasma mem-
brane of hepatocytes [17]. HFE binds the ubiquitously expressed TfR1 at a site that overlaps 
the transferrin binding domain, and Tf‐Fe2+ thus competes with HFE binding to TfR1. By 
contrast, TfR2 can bind both HFE and Tf‐Fe2+ simultaneously [18]. Although HFE and TfR2 
clearly contribute to hepcidin activation, the bone morphogenetic protein (BMP) signalling 
pathway is quantitatively the most critical. It has been proposed that HJV acts as co‐receptor 
that binds to bone morphogenetic protein (BMP) ligands and BMP type I and type II receptors 
on the cell surface. This complex (HJV‐BMP ligand‐BMP receptors) consequently induces an 
intracellular BMP signalling pathway which in turn activates the SMAD4 signalling pathway. 
Figure 2. Maintenance of systemic iron homeostasis regulated by hepcidin. Derived from: Tandara and Salamunic [14].
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The drosophila mothers against decapentaplegic (SMAD) complex translocate to nucleus and 
directly increases hepcidin gene transcription [19–21]. BMP/SMAD signalling cascade of HJV 
is important for basal regulation of hepcidin transcription [22]. Thus, HJV is central for hepci-
din expression, and the point of convergence of multiple regulatory inputs. Transmembrane 
protease, serine 6 (encoded by the TMPRSS6 gene) has been identified as an inhibitor of hep-
cidin activation by cleaving membrane HJV under normal conditions [11, 23, 24]. If TMPRSS6 
gene mutations occur, hepcidin levels increase and result in insufficient iron absorption [25].
Hepcidin synthesis is also dramatically induced by infection and inflammation. In particu-
lar, interleukin 6 (IL‐6) is the central inducer of hepcidin synthesis during inflammation [14, 
26, 27], which acts on hepatocytes and stimulates hepcidin production through signal trans-
ducer and activators of transcription (STAT3) signalling pathway [28]. Hepcidin mediated by 
IL‐6 often results in cellular iron retention and hypoferremia, thus anaemia develops due to 
restricted iron availability in haemoglobin synthesis [14]. In the condition in which anaemia/
hypoxia develops, hepcidin gene expression decreases along with the increase of erythro-
poietin expression. Tissue hypoxia increased erythropoiesis and further suppress hepcidin 
expression. Several bone marrow‐derivated signal molecules that regulate the process of 
erythropoiesis mediating hepcidin have been found, including growth differentiation factor 
15 (GDF15), twisted gastrulation protein homologue 1 (TWSG1), hypoxia inducible factors 
(HIF) and hormone erytropoetin [29–31]. Furthermore, iron responsive element (IRE)/iron 
responsive proteins (IRP) system also tightly regulates cellular iron uptake and storage and 
coordinatively keeps cell iron homeostasis.
Iron responsive proteins 1 (IRP1) and 2 (IRP2) in cytoplasmic can sense the level of iron in 
transit pool and bind specifically to RNA stem‐loops (iron responsive element, IRE), and post‐
transcriptionally modify the expression of proteins involved in iron metabolism [14].
2.3. Genetic variants associated with iron deficiency anaemia from genome‐wide 
association studies
The iron metabolism is tightly and precisely regulated by several interacting iron‐binding fac-
tors. The development of genome‐wide association studies (GWAS) has confirmed that the 
mutation of genes in iron metabolism, like transferrin, transferring receptors, matriptase‐2, hep-
cidin, may determine the phenotypic variation in iron homeostasis between individuals [32]. 
Mutations in the gene (HAMP) encoding hepcidin can increase iron absorption and lead to 
juvenile haemochromatosis [33]. Due to the same regulatory pathway, mutations in these genes, 
including those encoding HJV, HFE and TfR2, clearly result in iron loading syndromes [32].
However, limited information is available about gene variants associated with iron deficiency 
anaemia. The inherited disorders of iron metabolism played an important role in iron defi-
ciency anaemia. For example, in two association studies of iron metabolism disorders, the 
SNP rs235756 in BMP2 brings about the decrease of serum ferritin level [34, 35]. Mutations 
in the DMT1 gene occur in patients with microcytic anaemia, low serum ferritin and liver 
iron overload [36]. Studies also showed that mutations in the matriptase gene (TMPRSS6) 
cause iron‐refractory iron deficiency anaemia [11]. It has been suggested that the mutation 
G277S of the TF gene alone does not affect iron absorption in iron deficient women and a 
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combination of polymorphisms may be involved in iron metabolism [32, 37]. The recently 
determined mutation in the glutaredoxin 5 (GLRX5) gene leads to microcytic, hypochromic 
anaemia with iron overload and the presence of ringed sideroblasts in the bone marrow 
upon Perl’s staining [38]. According to the European Network of Rare Congenital Anaemia, 
62 rare anaemia subtypes are shown recently, including haemolytic anaemia and anaemia 
arising from mutations in genes that control duodenal iron absorption (e.g. SLC11A2), sys-
temic iron homoeostasis (e.g. TMPRSS6) or erythroid iron absorption and utilization [8]. The 
genetic forms of sideroblastic anaemia such as mutations in glutaredoxin 5, aminolevulinic 
acid synthetase 2 and ABCB7 genes provide the updated information.
3. Disease burden and adverse health consequences of iron deficiency 
anaemia in different life courses
3.1. Disease burden
WHO estimated that the highest prevalence of anaemia was in the population of pre‐school‐
aged children, pregnant and non‐pregnant women, but lower for school‐aged children, men 
and the elderly [8]. Data in 2010 showed more than 2.2 billion people were affected by anae-
mia and global prevalence of anaemia was 32.9%, and iron deficiency was reported as the 
most common cause of anaemia [4]. WHO estimates that 50% of cases are due to iron defi-
ciency, and regional disparities exist [4, 39]. In detail, results from studies conducted in the 
United States reported the prevalence of iron deficiency ranges from 4.5 to 18.0%. But the 
proportion of anaemia caused by iron deficiency in central Asia, south Asia and Andean Latin 
America were 64.7, 54.8 and 62.3%, respectively [8, 40].
In 2010, global anaemia causing 68.36 million years lived with disability (8.8% of total for all 
conditions) [4]. The distribution of anaemia prevalence was unbalanced across regions, central 
and West Africa and south Asia were the highest anaemia prevalence regions in middle‐ and 
low‐income areas, and high‐income areas had lowest anaemia prevalence (Table 1). In addi-
tion, this trend was similar among the higher risk population of anaemia (children under 5 
years, pregnant women from 15 to 49 years, non‐pregnant women from 15 to 49 years) [5].
3.2. Consequences of iron deficiency anaemia
The population of pre‐school‐aged children, pregnant and non‐pregnant women was the 
highest prevalence of anaemia [8], the consequences of iron deficiency anaemia among pre‐
school‐aged children, pregnant and non‐pregnant women should be emphasized.
The consequences of iron deficiency of pregnant women are multiple. First, iron deficiency dur-
ing pregnancy was significantly associated with increasing perinatal mortality. Evidence from 
six observational studies showed a combined odds ratio of 0.75 (association between anaemia 
and maternal mortality) associated with a 10 g/L increase in haemoglobin [41, 42]. In addition, 
the combined OR was 0.72 for perinatal mortality associated with a 10 g/L increase in hae-
moglobin [41, 42]. Another study (RCT) conducted in China found prenatal supplementation 
with iron‐folic acid was associated with a reduction in early neonatal mortality compared with 
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prenatal folic acid supplementation only [43]. Second, many studies have determinate the asso-
ciation between iron deficiency anaemia and pre‐term and low birth weight [44–46]. Evidence 
from a retrospective population‐based study showed maternal anaemia during pregnancy was 
risk factor for pre‐term delivery (OR = 1.2) and low birth weight (OR = 1.1) [44]. Results from 
a meta‐analysis reported that analysis of cohort studies showed a higher risk of pre‐term birth 
(OR = 1.21) and low birth weight (OR = 1.29) with anaemia in the first or second trimester 
of pregnancy [45]. Significant association between prenatal iron deficiency anaemia and low 
birth weight was also found in low and middle‐income counties [42]. Third, previous study 
reported that the fetal brain could be at risk when iron supply does not meet iron demand 
[47]. In addition, several observational studies reported the reverse effect of iron deficiency 
during pregnancy on intellectual development and motor development of children [48, 49]. 
One longitudinal study conducted in China found that prenatal iron deficiency anaemia in the 
third trimester is significantly associated with mental development of children [48]. Another 
prospective study conducted in Vietnam reported that prenatal iron deficiency anaemia hasad-
verse effects on child cognitive development [49].
Iron deficiency is more likely in women of reproductive age because of menstrual blood loss 
[50]. Results from some RCTs showed that iron improves cognitive ability, physical perfor-
mance and mood in iron‐depleted non‐anaemia women [51–53]. In detail, a study found iron 
supplementation improved physical performance and mood of female soldiers [51]. One study 
conducted in the United States reported iron status was significantly associated with cognitive 
Prevalence of anaemia (%)
Children (<5 years) Non‐pregnant women (15–49 
years)
Pregnant women (15–49 
years)
Middle‐ and low‐income areas
Central and west Africa 71 48 56
East Africa 55 28 36
South Africa 46 28 31
South Asia 58 47 52
East and southeast Asia 25 21 25
Central Asia, Middle East 
and north Africa
38 33 31
Oceania 43 28 36
Andean and central Latin 
America and Caribbean
33 19 27
Southern and tropical Latin 
America
23 18 31
Central and eastern Europe 26 22 24
High‐income areas 11 16 22
Table 1. Distribution of anaemia prevalence in middle‐ and low‐income areas by different population.
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ability in women of reproductive age. The iron‐sufficient women completed the cognitive tasks 
faster than women with iron deficiency anaemia, and got higher accuracy of cognitive function 
over a broad range of tasks [52]. Another study also reported the negative effect of maternal 
anaemia diagnosed postpartum on language comprehension of children [54].
Children under 5 years with iron deficiency anaemia test lower in social‐emotional, cognitive 
and motor development than control group children [47, 55–59]. For motor development, 
an observational study conducted in African‐America found poorer motor function in iron 
deficiency infants [56]. Another longitudinal study found lower motor scores in infants with 
chronic iron deficiency anaemia. In addition, long‐term effect of chronic iron deficiency anae-
mia in infancy on motor development in early adolescence was exist, and even iron treatment 
at the age of 12–23 months did not prevent long‐term effect of iron deficiency in infancy 
on motor development [57]. A study conducted in the United States showed positive effect 
of iron status of infants at 9 months on gross motor development and motor coordination/
sequencing [58]. For cognitive development, a meta‐analysis estimated that a 10 g/L haemo-
globin increase was significantly associated with a 1.73 increase in IQ tests [41]. Another study 
found children with iron deficiency anaemia at 54–60 months age had lower score for verbal 
reasoning test compared to non‐anaemia children [59].
Iron deficiency anaemia is prevalent in the elderly, particularly after the age of 80 [60]. Chronic 
blood loss, micronutrient‐related anaemia and renal disease are important mechanisms for 
low haemoglobin level [61]. A cohort study conducted in Taiwan reported iron deficiency was 
significantly associated with cardiovascular disease and all‐cause mortality in elderly [62]. 
A prospective study conducted in Korea found anaemia was associated with physical func-
tioning impairment and instrumental activities of daily living in elderly [63]. A Norwegian 
prospective study reported the significant association between low iron status and increasing 
risk of death from ischaemic heart disease [64]. Result from a cross‐sectional study conducted 
in England reported the significant relationship between iron status and symptoms of depres-
sion [65]. Many studies have extensively investigated the association between iron deficiency 
and productivity [42, 66], because the role of iron in oxygen transport to muscles and other 
tissues, and in other metabolic pathways by which iron deficiency can cause aerobic work 
capacity reduction [42]. Previous studies reported the positive effect of iron supplementation 
on work productivity of female cotton‐mill workers in China, female tea‐plantation work-
ers in Sri Lanka and rubber plantation workers in Indonesia [66, 67]. Iron deficiency would 
cause work performance reduction and has substantial economic consequences accordingly 
in countries in which physical labour is prevalent [42, 67].
In summary, the consequences of iron deficiency anaemia in different populations were multiple. 
For pregnant women with iron deficiency anaemia, the effects were mainly on perinatal mortal-
ity, pre‐term birth, low birth weight, offspring intellectual development and motor development. 
For non‐pregnant women, the effects were mainly on cognitive ability, physical performance and 
mood. For infant, the effects were mainly focus on further social‐emotional, cognitive and motor 
development. For elderly, the effects were mostly on cardiovascular disease, all‐cause mortality, 
physical functioning impairment, instrumental activities of daily living, increasing risk of death 
from ischaemic heart disease and symptoms of depression. The effect of iron deficiency in adults 
on work productivity was also reported.
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4. Standard diagnosis criteria of iron deficiency anaemia
At the population level, haemoglobin concentration is the most reliable indicator of anae-
mia. Meanwhile, measurement of haemoglobin concentration is frequently used as a proxy 
indicator of iron deficiency, because measurement of haemoglobin concentration is relatively 
inexpensive and easy. According to the criterion of World Health Organization, an adult man 
is considered as anaemic when the haemoglobin concentration is less than 130 g/L, whereas 
an adult woman is deemed anaemic when her haemoglobin concentration is less than 120 
g/L, and this cut‐off should be lowered to 110 g/L if the woman is in pregnancy. This cut‐off 
threshold is 115 g/L between 5 and 11 years, and 110 g/L under 5 years (Table 2) [8, 68].
Patients with severe anaemia can be usually detected by clinical examination such as pallor 
of eyelids, tongue, palms and nail beds [8, 39, 69]. In poor areas where laboratory testing is 
not feasible, clinical examination should be regularly used to monitor women and children. 
As the frequency of conjunctivitis caused redness even in anaemia patients, palm pallor is 
preferred to eyelid pallor as a clinical sign for diagnosis of young children. But, clinical mea-
sures are more subjective and have more room for error accordingly compare to haemoglobin 
concentration [39].
Because of the complex diagnosis of iron deficiency, use of several indicators in combina-
tion could be better for us to assess iron deficiency [8]. First, red cell indices on full blood 
counts show a reduced mean cell volume, which corresponds to microcytosis, and a reduced 
mean cell haemoglobin, corresponding to hypochromia. But the thresholds are not com-
monly agreed [70]. Second, mean cell haemoglobin and volume are widely available, sensi-
tive and inexpensive measures, but these indictors become abnormal only in longstanding 
iron deficiency. Moreover, mean cell volume could be normal if combined with nutrient 
deficiency [71].
Serum ferritin measurement is the most sensitive and specific test and widely used to identify 
iron deficiency [8, 39, 72], but it is spuriously elevate in malignancy, inflammatory conditions 
or liver disease. Serum ferritin below the cut‐off of 15 µg/L in patients older than 5 years could 
be diagnosed as iron deficiency [72]. However, results from previous study indicated that if 
the cut‐off of ferritin level increase to 30 µg/L, the diagnostic accuracy would be improved. 
The sensitivity would increase from 25 to 92% according, compared with the 12 µg/L (cut‐off 
value), and specificity was unchanged (98%) [73]. For the patients with malignant disease, 
acute and chronic inflammatory disorders and liver disease, cut‐off value equal or larger than 
50 µg/L could still be iron deficient [4, 72]. Results from previous studies suggested cut‐off of 
Children (0–14 years) Hb threshold (g/L) Adult (≥15 years) Hb threshold (g/L)
0.5–4 years 110 Non‐pregnant women 120
5–11 years 115 Pregnant women 110
12–14 years 120 Men 130
Table 2. Haemoglobin threshold in different population.
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100 µg/L for patients with chronic kidney disease [74], and suggested increasing cut‐off to 200 
µg/L in case of haemodialysis [75].
A low transferrin saturation level (less than 16%) also strongly indicates iron deficiency (iron 
supply insufficient to support normal erythropoiesis), but the threshold will increase to 20% 
in patients with inflammation. Because the serum iron will reduce with the increasing of total 
iron‐binding capacity if the patients with iron deficiency, and finally result in reduction in 
transferrin saturation [8, 39].
Serum soluble transferrin receptor (sTfR) is another useful biomarker in diagnosis of iron 
deficiency, and is not influenced by inflammation. The synthesis of transferrin receptors will 
increase if patients with iron deficiency and lead to an increase in sTfR accordingly [73]. But 
there are some limitations when using sTfR to determine iron deficiency. One of the limita-
tions is that if the patients with disorders associated with increased erythropoiesis (haemolytic 
anaemia, chronic lymphocytic leukaemia), concentrations of sTfR can be raised accordingly. 
Another limitation is that the guidelines are only published in the UK, but standardized cut‐offs 
worldwide are still absent [75].
Recently, bone marrow aspiration is another option to assess iron stores, and thought of as 
the highly specific and not affected by inflammation for diagnosis of iron deficiency. But it is 
not used frequently only when other tests are conflicting or negative. As it is expensive and 
affected by recombinant human erythropoietin, it is uncomfortable for the patients [8, 39].
For diagnosis of iron deficiency anaemia, it is important to consider the whole picture rather 
than relying on single test results when determining the iron deficiency. The diagnosis of iron 
deficiency for the patients with inflammation is challenging and also cannot be determined 
on the basis of a single test result.
5. Therapy choice in clinical practices
The goals of treating iron deficiency anaemia are to treat its underlying cause and supply enough 
iron to normalize haemoglobin concentrations and replenish iron stores. Considering its cause 
and severity of iron deficiency anaemia, treatments may include dietary changes and supple-
ments, medicines and surgery. Severe iron deficiency anaemia may require a blood transfusion, 
iron injections or intravenous (IV) iron therapy, which may need to be addressed in a hospital.
5.1. Oral iron therapy
Medical care starts with establishing the diagnosis and reason for the iron deficiency. Iron 
supplementation is used to prevent iron deficiency anaemia in at‐risk populations, or to treat 
patients with proven disease. Treatment with oral iron supplements is simple, inexpensive 
and a relatively effective way of treating iron deficient conditions. WHO has recommended 
daily iron supplementation with 60 mg of elemental iron to prevent iron deficiency in men-
struating adolescent girls and women, and 2 mg/kg daily in children aged 0–5 years and 30 
mg daily in children aged 5–12 years [76–78]. In general, four common iron preparations 
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are often adopted, i.e. ferrous sulphate, ferrous sulphate exsiccated, ferrous gluconate and 
ferrous fumarate. When side effects occur (dark stools, constipation, stomach irritation and 
heartburn), iron can be taken with meals, but doing so decreases absorption to 40% [8]. The 
best source of iron is red meat, especially beef and liver. The body tends to absorb iron from 
meat better than iron from non‐meat foods. However, some non‐meat foods can also help 
you raise your iron levels. Furthermore, Vitamin C helps the body absorb iron, whose good 
sources are vegetables and fruits, especially citrus fruits.
In most patients, the iron deficiency should be treated with oral iron therapy, and the under-
lying etiology should be corrected so the deficiency does not recur. However, there are cases 
that iron supplements are inappropriate to patients, for example, those who have a microcytic 
iron‐overloading disorder (e.g. thalassemia and sideroblastic anaemia).Therefore, it may be 
necessary to identify the etiology of the anaemia, such as gene mutation related to iron metab-
olism, occult blood loss undetected with chemical testing of stool specimens; for identification 
of a source of bleeding that requires endoscopic examinations or angiography; or for treat-
ment of an underlying major illness (e.g. neoplasia and ulcerative colitis).
5.2. Intravenous (IV) iron therapy
The British Society of Gastroenterology guidelines suggest that all patients require iron sup-
plementation and that parenteral iron can be used if oral preparations are not well tolerated. 
For therapeutic iron supplementation, treatment with IV iron in some clinical situations could 
present some advantages over oral iron, such as faster and higher increases of haemoglobin 
(Hb) levels and body iron stores. Friedrisch et al. suggest the main clinical indications for IV 
iron treatment, which contains post‐gastrectomy/bariatric surgery, anaemia of chronic kidney 
disease, intestinal malabsorption syndromes, anaemia associated to inflammatory diseases, 
inflammatory bowel diseases, anaemia of cancer, intolerance to oral iron or non‐compliance 
to an oral regimen, iron‐refractory iron deficiency anaemias and so on [79].
Recently, three new IV iron compounds (ferric carboxymaltose [FCM], iron isomaltoside 1000 
[Monofer®] and Ferumoxytol [FeraHeme®]) have been released for clinical use in patients 
with Iron Deficiency Anaemia (IDA) [80–82]. Do not administer IV iron therapy to patients 
who should be treated with oral iron, as anaphylaxis may result. Uncommonly, post‐meno-
pausal women are unresponsive to iron supplementation, including parenteral iron, because 
they have primary defective iron reutilization due to androgen deficiency. This condition 
responds only to androgen replacement. Danazol is a reasonable choice for these patients, as 
it is less masculinizing.
6. Public health strategies to reduce iron deficiencies in high‐burden 
areas
Although the global anaemia burden has been actually improved and age‐standardized preva-
lence of anaemia was down from 33.3% in 1990 to 27% in 2013, according to the analysis based 
on 188 countries, 20 age groups, the total population with anaemia increased from 1.83 billion in 
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1990 to 1.93 billion in 2013 [2]. Developing countries account for more than 89% of the burden, 
with the greatest prevalence in central and western sub‐Saharan African and greatest number 
of case in South Asia. Children with the highest burden of anaemia consistently have improved 
less than adults [2]. Iron deficiency anaemia is the dominant cause of anaemia globally and in 
most populations, accounting for 62.6% of the total of anaemia cases, and IDA was also the 
greatest causes of anaemia‐related disability with 60% of total years lived with disability (YLD) 
[2, 83]. Monitoring and controlling IDA has been the crucial driver of reduced global anae-
mia burden since 1990 [2, 3]. Individual‐level and population‐level interventions targeted iron 
deficiency anaemia were implemented and the efficacy and effectiveness of these intervention 
strategies were also evaluated with a priority in high‐risk, high‐burden population such as pre‐
school‐children and pregnant women. Especially, further actions on iron deficiency anaemia 
prevention and treatment are highly required in order to reach the global nutrition targets of a 
50% reduction of anaemia in women of reproductive age by 2025 [84].
The World Health Organization (WHO) has published a series of guidelines that support 
policies for the prevention and control of iron deficiency anaemia targeted on population 
in highest burden of IDA [78, 85–88]. The most common cause of iron deficiency anaemia 
in high‐burden areas is prolonged negative iron balance, caused by inadequate dietary iron 
intake or absorption, increased needs for iron during pregnancy or growth periods, and 
increased iron losses as a result of menstruation and parasitic infections [84].
Public health strategies to prevent and control iron deficiency anaemia include improvements 
in dietary diversity; food fortification with iron, folic acid and other micronutrients; distribu-
tion of iron‐containing supplements. The efficacy and effectiveness of different strategies were 
evaluated, based on the evidence from the community‐based large‐scale intervention studies.
6.1. Improvements in dietary diversity
Health education about food and nutrition such as dietary counselling is one of three recommended 
intervention strategies to decrease the IDA burden. Although dietary counselling commonly 
resulted in a better dietary intake profile in targeted subpopulation, such as breastfed for longer and 
had non‐human milk introduced later among infant, consumed more meat and had diets with better 
iron bioavailability in relation to the children or pregnant women; however, this kind of interventions 
was not sufficient to prevent occurrence of anaemia, ID or IDA in population with high IDA burden 
[89–91].
6.2. Food fortification with iron
Food fortification as one of the leading public health interventions was recommended to 
prevent and control micronutrient deficiencies including iron deficiency and iron deficiency 
anaemia by adding the micronutrients containing iron to processed food vehicles, or home 
fortification. The choice of processed food vehicles varies widely by region and context, 
depending on the subpopulation targeted, food consumption and acceptability, food avail-
ability and sustainability, as well as the financial and technical concerns. The staple food is the 
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most commonly used as vehicle of fortification, in addition, milk powder, beverages, biscuits, 
the most commonly used sauce, such as soy sauce, drink and water, can also be used as forti-
fied foods [92–104].
More than 80 countries have mandated fortification of wheat and maize flour with at least iron 
and folic acid in 2015 [93]. A review of efficacy and effectiveness of flour fortification programmes 
on iron status and anaemia found that flour fortification is associated with consistent reductions 
in low ferritin prevalence in women, but not in children. Further, a reduction in anaemia preva-
lence was observed in only one‐third of the subgroups of women and children studied [93].
A recently published review on the effect of multiple micro‐nutrients (MMN) containing iron‐
fortified non‐dairy beverages among school‐aged children in low‐middle‐income counties 
showed a clear benefit of MMN fortified non‐dairy beverages intervention from 8 weeks to 6 
months on anaemia (42% reduction in prevalence), iron deficiency (66% reduction in prevalence) 
and iron deficiency anaemia (83% reduction in prevalence) compared to iso‐caloric controls [99].
Biscuits have been identified to be an ideal vehicle for fortification for school‐aged children 
due to its convenience with regard to storage, distribution and long shelf life. A nutrition 
intervention trial conducted in India showed that iron‐fortified biscuits led to a significant 
enhancement in haemoglobin status of anaemic school children in rural areas [98]. Another 
study showed that maize porridge fortified with multi‐micronutrient powder contained low 
dose, highly bioavailable iron can reduce the prevalence of IDA in pre‐school children [102]. 
Home fortification with multi‐micronutrient powder with low dosages of bioavailable iron 
may therefore be a promising strategy to improve iron status among children.
A study involved 3029 students of the boarding schools in the 27 provinces in China showed 
that iron‐fortified soy sauce could be effective for the improvement of the haemoglobin level 
and reduce anaemia prevalence of boarding school students [97].
The beneficial of fortified complementary feeding supplement on the growth of young chil-
dren aged 6–23 months have been confirmed by a large number of nutrition intervention 
programme conducted in population with low socio‐economic status. Furthermore, the risk 
of anaemia among young children was significantly reduced after the daily fortified com-
plementary feeding supplement introduced to infant diet in rural area, which implied that 
fortified complementary feeding supplement could be a best intervention strategy target on 
young children anaemia [105–112].
The successful implementation of food fortification programme commonly requires govern-
ment‐driven and multi‐stakeholder participation, which has also become an obstacle to its 
sustainability.
6.3. Iron supplementation
Iron supplementation, provided in capsule, tablet or syrup form, is most suitable in contexts 
where certain subpopulation may not be reached, or when iron requirements may not be met 
by other intervention strategies.
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A series of systematic reviews based on randomized control trial have been carried out to 
assess the effect of daily iron supplementation on haematologic and non‐haematologic out-
comes in high‐burden subpopulations [113–119]. In children aged 4–23 months, daily iron 
supplementation effectively reduces anaemia by 39%, iron deficiency by 70% and iron defi-
ciency anaemia by 86% [117]. In 2–5‐year‐old children, daily iron supplementation increases 
haemoglobin and ferritin; however, the evidence on the effect of iron supplementation on 
anaemia, iron deficiency and iron deficiency anaemia is limited [114]. In primary‐school‐aged 
children (5–12‐year old), iron supplementation reduced the risk of anaemia by 50% and the 
risk of iron deficiency by 79% [116, 118].
The World Health Organization has published a series of iron supplementation guidelines, 
which provides global, evidence‐based recommendations on the daily or intermittent use of 
iron supplements for high‐burden subpopulation as a public health intervention to improve 
iron status and reduce the risk of iron deficiency anaemia in childhood, adolescence, preg-
nancy and lactation [85–88]. WHO suggested iron supplementation scheme targeted on variety 
of subpopulation was summarized in Table 3. In summary, the establishment of effective 
strategies, an integrated, multifactorial and multi‐sectoral approach, is required to achieve 
IDA control target [84].
Target group Supplementation 
composition
Supplement form Frequency Duration Settings
Anaemic 
pregnant women
120 mg of 
elemental iron 
and 400 µg folic 
acid
Daily Until women's 
Hb concentration 
rises to normal, 
then followed 
by the standard 
daily antenatal 
iron dose
Where prevalence 
of anaemia in 
pregnant women 
is 40% or higher
Non‐anaemic 
pregnant women
30–60 mg of 
elemental iron 
and 400 µg folic 
acid
Daily During 
pregnancy
Where prevalence 
of anaemia in 
pregnant women 
is 40% or higher
Non‐anaemic 
pregnant women
120 mg of 
elemental iron 
and 2800 µg of 
folic acid
weekly During 
pregnancy
Where anaemia 
prevalence 
among pregnant 
women is less 
than 20%
Postpartum 
women
iron 
supplementation, 
alone or 
combination with 
folic acid
6–12 weeks 
following 
delivery
Where 
gestational 
anaemia is of 
public health 
concern
Infants and 
young children 
aged 6–23 
months
10–12.5 mg 
elemental iron
Drops/syrups Daily Three consecutive 
months in a year
Where the 
prevalence of 
anaemia in 
infants and 
young children is 
40% or higher
Current Topics in Anemia16
7. Conclusion—key results
Considering the complexity of the regulatory network required to maintain iron homeostasis, 
future fine‐mapping studies, including rare and uncommon variants, and functional stud-
ies should be undertaken to better characterize loci and to identify the functional variants 
directly influencing iron levels in iron deficiency anaemia.
Target group Supplementation 
composition
Supplement form Frequency Duration Settings
Pre‐school‐age 
children (24–59 
months of age)
30 mg elemental 
iron
Drops/syrups/
tablets
Daily Three consecutive 
months in a year
Where the 
prevalence of 
anaemia in 
infants and 
young children is 
40% or higher
Pre‐school‐age 
children (24–59 
months of age)
25 mg of 
elemental iron
Drops/syrups Weekly 3 months of 
supplementation 
followed by 3 
months of no 
supplementation 
after which the 
provision of 
supplements 
should restart
Where the 
prevalence of 
anaemia in pre‐
school or school‐
age children is 
20% or higher
School‐age 
children (5–12 
years of age)
30–60 mg 
elemental iron
Tablets or 
capsules
Daily Three consecutive 
months in a year
Where the 
prevalence of 
anaemia in 
infants and 
young children is 
40% or higher
School‐age 
children (5–12 
years of age)
45 mg of 
elemental iron
Drops/syrups Weekly 3 months of 
supplementation 
followed by 3 
months of no 
supplementation 
after which the 
provision of 
supplements 
should restart
Where the 
prevalence of 
anaemia in pre‐
school or school‐
age children is 
20% or higher
Menstruating 
adult women and 
adolescent girls 
(non‐pregnant 
females in the 
reproductive age 
group)
30–60 mg 
elemental iron
Tablets Daily Three consecutive 
months in a year
Where the 
prevalence of 
anaemia in 
menstruating 
adult women and 
adolescent girls is 
40% or higher
Table 3. WHO suggested scheme daily iron supplementation in different subpopulation.
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New parameters which can give useful information about the iron availability for erythro-
poiesis and the erythropoietic activity of the bone marrow, and with stable to inflammatory 
conditions, should be developed for the early detection of iron deficiency, monitoring effect of 
iron supplementation and treatment, and discrimination the types of anaemia.
Intravenous iron formulation for rapid and high‐dose replenishment of depleted iron stores 
with very low immunogenic potential is ideal alternative choice for the treatment of iron defi-
ciency anaemia. Iron supplementation and fortification, as two key public health strategies 
in reducing the iron deficiency anaemia burden, should be selected in terms of the certain 
population subgroups targeted. The establishment of effective strategies, an integrated, mul-
tifactorial and multi‐sectoral approach, is required to achieve IDA control target.
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